Alimera Sciences, Inc. · Alpharetta, GA United States ·(NASDAQ (GM): ALIM)

Alimera Sciences' tunnel vision is a real asset. The biopharmaceutical company specializes in prescription ophthalmic pharmaceuticals, particularly those aimed at treating ocular diseases affecting the retina. Alimera's most advanced product candidate, Iluvien, is an intravitreal insert used in the treatment of diabetic macular edema (DME); DME, a retinal disease affecting diabetics, can lead to severe vision loss and blindness. Iluvien, which is effective for up to 36 months, may also have the potential to affect other ophthalmic diseases, such as the wet and dry forms of age-related macular degeneration (AMD) and retinal vein occlusion (RVO). Alimera Sciences has withdrawn its IPO application. To read the full description, subscribe now.